Atara Biotherapeutics Presents Positive Efficacy and Safety Results for Patients with Epstein-Barr Virus-Associated Leiomyosarcoma (EBV+ LMS)

Author's Avatar
Dec 15, 2018
Article's Main Image
  • Second EBV‑associated solid tumor with encouraging responses to tab-cel®
  • Tab-cel® safety appears consistent with a favorable risk profile and previous observations
  • Results were presented today in an oral session at the European Society for Medical Oncology Immuno-Oncology Congress 2018